Merck AIDS studies
L-697,639 reverse transcriptase inhibitor began early clinical studies (40 patients enrolled) during the second week of December. Studies are being conducted under auspices of NIAID. Based on the accelerated pace of research throughout the industry, Merck Chairman Vagelos has previously predicted that a major new product will enter the AIDS category within the next two years.
You may also be interested in...
The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.
The US agency has announced another month of webinars aimed at labs and manufacturers that are developing – or have developed – diagnostic tests for the novel coronavirus.
The European Medicines Agency says its rolling review tool should speed up the evaluation of AstraZeneca’s COVID-19 vaccine.